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Abstract
 
We identified previously a patient with recurrent bacterial infections who failed to respond to
gram-negative LPS in vivo, and whose leukocytes were profoundly hyporesponsive to LPS and
IL-1 in vitro. We now demonstrate that this patient also exhibits deficient responses in a skin
blister model of aseptic inflammation. A lack of IL-18 responsiveness, coupled with diminished
LPS and/or IL-1–induced nuclear factor–
 
 
 
B and activator protein-1 translocation, p38 phos-
phorylation, gene expression, and dysregulated IL-1R–associated kinase (IRAK)–1 activity in
vitro support the hypothesis that the defect lies within the signaling pathway common to
toll-like receptor 4, IL-1R, and IL-18R. This patient expresses a “compound heterozygous”
genotype, with a point mutation (C877T in cDNA) and a two-nucleotide, AC deletion (620–
621del in cDNA) encoded by distinct alleles of the 
 
IRAK-4
 
 gene (GenBank/EMBL/DDBJ ac-
cession nos. AF445802 and AY186092). Both mutations encode proteins with an intact death
domain, but a truncated kinase domain, thereby precluding expression of full-length IRAK-4
(i.e., a recessive phenotype). When overexpressed in HEK293T cells, neither truncated form
augmented endogenous IRAK-1 kinase activity, and both inhibited endogenous IRAK-1 ac-
tivity modestly. Thus, IRAK-4 is pivotal in the development of a normal inflammatory re-
sponse initiated by bacterial or nonbacterial insults.
Key words: immunodeﬁciency • TLR4 • IL-1R • inﬂammation • signal transduction
 
Introduction
 
In 1997, Kuhns et al. (1) described a patient with a 15-yr
history of recurrent bacterial infections who exhibited a
profound defect in the capacity to respond to LPS in vivo
or LPS and rIL-1 in vitro, whereas responses to rTNF-
 
 
 
 or
platelet-activating factor remained intact. The patient’s
phagocytes expressed CD14 normally and bound LPS in a
specific manner, suggesting a defect early in the signal
transduction pathway. That paper was published before
identification of toll-like receptor (TLR) 4 as the primary
LPS signal transducing molecule (2, 3), or the recognition
that TLR4 and IL-1R share a common signaling cascade
that leads to nuclear factor (NF)–
 
 
 
B translocation, cytokine
gene expression, and increased expression of costimulatory
molecules (4). In response to LPS or IL-1, an adaptor mol-
ecule, MyD88, is recruited to and interacts with the intra-
cytoplasmic toll/IL-1R (TIR) domain of TLR4 or IL-1
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Abbreviations used in this paper:
 
 AP-1, activator protein-1; CDS, coding se-
quence; Cox-2, cyclooxygenase-2; DD, death domain; EMSA, electro-
phoretic mobility shift assay; IRAK, IL-1R–associated kinase; MBP,
myelin basic protein; NF, nuclear factor; TIR, toll/IL-1R; TLR, toll-like
receptor; TRAF6, TNF receptor–associated factor 6.T
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through its own COOH-terminal TIR domain (for review
see reference 5). MyD88 also possesses an NH
 
2
 
-terminal
death domain (DD) that enables recruitment of a serine/
threonine kinase, IL-1R–associated kinase (IRAK)–1, to
the receptor complex through a homotypic interaction via
its NH
 
2
 
-terminal DD (for review see reference 6). Burns et
al. (7) reported recently that the region of MyD88 that lies
between its DD and TIR domains is essential for MyD88
binding of a related kinase, IRAK-4, that, in turn, phos-
phorylates IRAK-1 (7, 8). Once phosphorylated by IRAK-4,
IRAK-1 autophosphorylates a different site, dissociates
from the receptor complex, and interacts through its
COOH terminus with TNF receptor–associated factor 6
(TRAF6), leading ultimately to NF-
 
 
 
B activation (for re-
view see reference 6). A variant of MyD88 that lacks the
region between the DD and TIR domains fails to bind
IRAK-4 and, thereby, inhibits IRAK-4–mediated phos-
phorylation of IRAK-1 and downstream signaling (7). The
importance of IRAK-4 in LPS and IL-1 signaling is further
supported by the finding that mice with a targeted muta-
tion in 
 
IRAK-4
 
 exhibit an LPS- and IL-1–hyporesponsive
phenotype (9) similar to that of our patient. We have iden-
tified two distinct 
 
IRAK-4
 
 mutations in this patient as fol-
lows: (a) a point mutation (C21175T in genomic DNA;
C877T in cDNA) and (b) a two-nucleotide AC deletion
(15978–15979del in genomic DNA; 620–621del in
cDNA) that are expressed on distinct alleles inherited from
phenotypically normal parents. Both mutations result in
truncations within the kinase domain of IRAK-4 protein,
resulting in a recessive phenotype. In contrast to overex-
pression of WT 
 
IRAK-4
 
, which reproducibly enhanced
endogenous IRAK-1 kinase activity in HEK293T cells,
both mutated forms not only failed to augment endoge-
nous IRAK-1 kinase activity but also were modestly inhib-
itory. Thus, failure to express a WT IRAK-4 precludes re-
cruitment and activation of key downstream signaling
molecules and underlies the profoundly deficient inflam-
matory response seen in this patient.
 
Materials and Methods
 
Case Report. 
 
The patient is a 21-yr-old woman who was the
subject of an earlier work (1). At the time of the previous paper,
she had 13 life-threatening infections in the first 15 yr of life char-
acterized by minimal or no febrile responses. These included
 
Streptococcus pneumoniae
 
 meningitis at 9 and 20 mo, endophthalm-
itis with 
 
Neisseria meningitidis
 
 at 13 mo, chronic serous otitis me-
dia, an abdominal abscess with gram-positive diplococci (culture-
negative) at 3 yr, and episodes of 
 
Staphylococcus aureus
 
 cellulitis at
3, 6, and 12 yr. During treatment of an intraabdominal abscess at
3 yr, she developed neutropenia with an absolute neutrophil
count of 1,000–2,000 cells/mm
 
3
 
 that has persisted to present.
Other infections included 
 
Clostridium septicum
 
 infection with gan-
grene of the left leg at 9 yr, requiring total left leg amputation
with hip disarticulation, associated with septic shock and acute re-
spiratory distress syndrome. At 13 yr, she had nasal polyps culture
positive for 
 
Streptococcus intermedicus
 
 and 
 
Gemella morbillorum
 
. Since
the original report, she has had five hospitalizations, but none
with culture-positive infection. At 17 yr, she was hospitalized for
a ruptured kidney cyst that required no antibiotics. She had two
hospitalizations at 18 yr for vague abdominal complaints without
diagnosis after a course of antibiotics for culture-negative cutane-
ous abscesses, one admission at 19 yr for ulcers of the left elbow,
arm, and axilla (probably from poorly fitting crutches) and left eye
inflammation of an unknown infection that was responsive to an-
tibiotics, and one admission at 20 yr for chronic right knee pain
with progressive symptoms of erythema and edema, and a diag-
nosis of degenerative arthritis, but without evidence of infection.
Growth and development have been normal and she has gone
through normal puberty with menarche, although her menstrual
cycles have been irregular. She has done better clinically since she
has passed through adolescence, as evidenced by lack of culture-
positive severe infections. She has never had significant problems
with viral or fungal infections. Her neutropenia persists and her
neutrophil count rises to 
 
 
 
4,000 cells/mm
 
3
 
 at times of acute in-
flammation. The patient, her mother, maternal grandmother,
great maternal aunt, and great maternal grandmother have poly-
cystic kidney disease. There is no family history of recurrent in-
fections.
 
Reagents. 
 
Protein-free 
 
Escherichia coli
 
 K235 LPS was prepared
by the method of McIntire et al. (10). Human rIL-1
 
 
 
, rTNF-
 
 
 
,
and rIL-18 were obtained from R&D Systems. PMA and
ionomycin were purchased from Sigma-Aldrich. Abs to
human IRAK-1 (Upstate Biotechnology), phosphorylated p38
(Promega), total ERK 1,2 (New England Biolabs, Inc.), and Flag
(M2; Sigma-Aldrich) were used for Western blot analysis. All kits
were used according to the manufacturers’ instructions.
 
Isolation of PBMCs and Neutrophils. 
 
Because the patient had a
history of bacterial infection and was persistently neutropenic,
leukopheresis and elutriation were not viable options and limited
the yield of leukocytes collected per visit. Peripheral blood from
normal volunteers was obtained through the Frederick Research
Donor Program (Protocol OH00-C-N046) or the Warren Mag-
nuson Clinical Center, National Institutes of Health (NIH; Pro-
tocol 99-CC-0168) and from the patient through the Warren
Magnuson Clinical Center, NIH (Protocol 93-I-0119). Normal
and patient blood were anticoagulated with citrate dextrose solu-
tion USP formula A (Baxter Healthcare). Whole blood, diluted
with HBSS (BioWhittaker, Inc.) without divalent cations, was
centrifuged over a discontinuous gradient cushion (LSM
 
®
 
; ICN
Biomedicals) for 30 min at 400 
 
g
 
 at room temperature. PBMCs
were harvested from the top of the gradient and washed two
times with HBSS. Both freshly prepared and cryopreserved cells
were used in this study.
The neutrophil/erythrocyte pellet was suspended in an equal
volume of HBSS. The cell suspension was diluted with dextran
(1.5%
 
final
 
, mol wt = 200,000–500,000 g/mol; Amersham Bio-
sciences) and allowed to sediment for 20 min before centrifuga-
tion at 200 
 
g
 
 for 10 min. Contaminating erythrocytes were re-
moved two times by hypotonic lysis using 0.2% PBS for 30 s,
followed by an equal volume of 1.6% PBS to restore isotonicity.
Neutrophils were counted on an automated cell counter (model
T540; Coulter Corp.).
 
Induction of Blisters and Analysis of Inflammatory Response.
 
Blisters were raised on forearms of healthy, normal volunteers and
the patient as described previously (11) after informed consent
(NIH Clinical Center; Protocol No. 90-I-120). The roof of the
blister was removed aseptically and a sterile, 8-well chamber de-
vice placed over the exposed dermal floor. Autologous, heat-
inactivated serum (0.8–1.0 ml diluted to 70% with HBSS with di-
valent cations) was added to each well. At the indicated times, se-
rum was collected from the wells and the exudate cells harvestedT
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by centrifugation. IL-6 and IL-8 levels in sera were determined
by ELISA (R&D Systems; lower detection limits were 3.5 and
18.1 pg/ml, respectively). C5a levels were determined by radio-
immunoassay (lower detection limit, 10 ng/ml; Amersham Bio-
sciences). Exudate cells were resuspended in HBSS (without di-
valent cations), counted by hemocytometer, and identified by
differential staining (Diff-Quik
 
®
 
, Baxter Scientific Products).
 
In Vitro Functional Assays. 
 
To assess IL-18 responsiveness, T
cells were purified from PBMCs by negative selection using T
cell enrichment columns (R&D Systems), and cultured at 10
 
6
 
cells/ml in RPMI 1640 (BioWhittaker, Inc.) with 10% FCS (Hy-
clone), 50 
 
 
 
M 2
 
 
 
ME (Sigma-Aldrich), 10 
 
 
 
g/ml PHA (Sigma-
Aldrich), and 1 ng/ml rIL-12 (R&D Systems). After 3 d, T cells
were harvested, washed, and resuspended at 10
 
6
 
 cells/ml RPMI
1640 with 10% FCS and cultured for 48 h in the presence of 20
ng/ml rIL-18 or PMA/1 
 
 
 
M ionomycin. IFN-
 
 
 
 was measured
in culture supernatants by ELISA (R&D Systems).
For all other in vitro assays, except the IRAK-1 kinase assay,
PBMCs were cultured in RPMI 1640 supplemented with 2 mM
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
 
 
g/ml streptomycin, 10
mM Hepes, 0.3% sodium bicarbonate, and 10% human AB se-
rum. For detection of NF-
 
 
 
B and activator protein-1 (AP-1)
translocation, electrophoretic mobility shift assays (EMSAs) were
performed as described previously (12). Western blot analysis of
whole cell lysates was used to detect phosphorylated p38 kinase
or total ERK 1,2 as described previously (13). To detect Flag-
tagged IRAK4 proteins, HEK293T cells were cultured overnight
in 100-mm Petri dishes (2.5 
 
 
 
 10
 
6
 
 cells/dish) and cotransfected
for 3 h with normal or mutated pRK7-IRAK4 expression vectors
and control empty vector (pCDNA3; total amount of plasmid
DNA was adjusted to 10 
 
 
 
g/dish by complementing with
pCDNA3) using SuperFect Transfection Reagent (QIAGEN).
After 48 h, cellular extracts were prepared (13). Proteins were re-
solved on 4–20% SDS-PAGE gels (Invitrogen), transferred to Im-
mobilon P membranes, and analyzed by immunoblotting with 1
 
 
 
g/ml anti-Flag mAb and secondary horseradish peroxidase–con-
jugated anti–mouse IgG (Amersham Biosciences; 1:12,500 dilu-
tion). Bands were detected with enhanced chemiluminescence
plus reagents (Amersham Biosciences).
Steady-state levels of mRNA for LPS-inducible genes (e.g.,
TNF-
 
 
 
, GM-CSF, and cyclooxygenase-2 [Cox-2]), and for
genes required for TLR4 and IL-1
 
 
 
 signaling, were analyzed by
reverse transcription (RT)-PCR with Southern blot analysis as
described previously (14). A list of primer sets and probes used to
detect specific mRNA species will be provided upon request.
Because the number of PBMCs was limited for any one exper-
iment, the IRAK-1 kinase assay was performed on purified neu-
trophils exactly as described for elutriated monocytes (14). Fifty
million neutrophils per time point were treated, and cell lysates
were immunoprecipitated with anti–IRAK-1 Ab. Immunopre-
cipitates were assayed for the ability to phosphorylate myelin ba-
sic protein (MBP). The radioactive signal was detected using a
PhosphorImager (Molecular Dynamics).
 
Cloning and Sequencing of IRAK-1 and IRAK-4 Genes. 
 
Total
RNA was isolated from PBMCs obtained from five healthy vol-
unteers and the patient using RNeasy kit (QIAGEN), treated with
RNase-free DNase I (QIAGEN) to eliminate genomic DNA, re-
purified, and quantified spectrophotometrically. cDNA was ob-
tained by RT with random hexamers and avian myeloblastosis vi-
rus reverse transcriptase using Reverse Transcription System
(Promega). For IRAK-1 sequencing, different portions of the
coding sequence (CDS) were amplified by PCR using Pfu Turbo
DNA polymerase (Stratagene) with the highest fidelity (15), Gen-
N-hancer (Geno Technology, Inc.), and primers shown in
Table SI (available at http://www.jem.org/cgi/content/full/
jem.20030701/DC1). Sequences from multiple reactions were
compared with each other and to GenBank/EMBL/DDBJ acces-
sion nos. L76191, NM_001569, dbSNP: 1059702, and P51617
and AAC41949 for IRAK-1 cDNA and protein sequences using
Blast search programs (http://www.ncbi.nlm.nih.gov/BLAST;
National Center for Biotechnology Information [NCBI], NIH).
The IRAK-4 mRNA CDS was amplified in PCR reactions
using primer pairs shown in Table SII (available at http://
www.jem.org/cgi/content/full/jem.20030701/DC1). PCR prod-
ucts were cloned for sequencing into the pCR4BluntTOPO
vector using Zero Blunt TOPO PCR cloning kit (Invitrogen)
followed by one shot chemical transformation into Top10 chem-
ically competent cells. For every analysis, 10 colonies contain-
ing cloned PCR products from normal volunteers and 10
from the patient were picked and plasmid DNA isolated with
QiaPrep Spin Miniprep kit (QIAGEN). After verification of the
presence of the PCR products in the vector by restriction analysis
with EcoRI, 
 
 
 
3 samples of plasmid DNA from each group were
sequenced with both M13 universal sequencing and gene-specific
primers. The sequences obtained from normal volunteers and the
patient were compared with each other as well as against the
 
IRAK-4
 
 GenBank/EMBL/DDBJ accession nos. AY186092 and
AF445802 for 
 
IRAK-4
 
 genomic DNA and cDNA, respectively,
and Blast search programs. Sequencing was also performed on
PCR products amplified from genomic DNA with primers en-
compassing the sequence of genomic DNA that corresponds to
that of cDNA where mutations were identified. Genomic DNA
was isolated with a Blood and Cell Culture DNA minikit
(QIAGEN) and amplified by PCR using Pfu Turbo DNA poly-
merase and the following primers: 5
 
 
 
-ACAACTGGGTTGC-
CATTTTATTAGGTG-3
 
 
 
 (forward, start 20846) and 5
 
 
 
-
CCAGATGCTCTAGGTTAAGACCTGCAT-3
 
 
 
 (reverse, start
21342), annealing temperature 60
 
 
 
C; 5
 
 
 
-GATCACCAAACA-
GAGTTCTCAAGAAAAA-3
 
 
 
 (forward, start 15662) and 5
 
 
 
-
GACATAACCACATTTTTCTAGGGGTAGG-3
 
 
 
 (reverse,
start 16208), annealing temperature 59
 
 
 
C; and 5
 
 
 
-TGGGTAGG-
TAGACTAGACCCACTCAAA-3
 
 
 
 (forward, start 15588) and
5
 
 
 
-GGCACACTATGAAGCAACTCTTTCTTT-3
 
 
 
 (reverse,
start 16059), annealing temperature 59
 
 
 
C. PCR products and
plasmids obtained by cloning PCR products into pCR4BluntTOPO
vector were sequenced using Big Dye Terminator Cycle Se-
quencing Kit, v. 3.0 (Applied Biosystems). The entire 
 
IRAK-4
 
CDS PCR cloning and sequencing was repeated three times,
whereas different portions of the 
 
IRAK-4
 
 CDS were PCR-
cloned and sequenced twice.
Sequencing was performed at the Biomedical Instrumentation
Center (Uniformed Services University of the Health Sciences
[USUHS]) and the Biopolymer Facility (University of Maryland,
Baltimore). 
 
IRAK-4
 
 mutations were confirmed in a Clinical
Laboratory Improvement Amendments-certified laboratory
(GeneDx, Inc.).
 
Site-directed Mutagenesis. 
 
Site-directed mutagenesis of WT
human IRAK-1 and IRAK-4 expression vectors (pRK5-IRAK-1
and pRK7-IRAK-4; Tularik, Inc.) was performed using the
QuickChange Site-Directed Mutagenesis Kit (Stratagene). The
primers 5
 
 
 
-GAGCCCGCCCCTTTCCGTTTTGCTG-3
 
 
 
 (for-
ward) and 5
 
 
 
-CAGCAAAACGGAAAGGGGCGGGCTC-3
 
 
 
 (re-
verse) were used to introduce T to C substitution at nucleotide
666 (i.e., 665–667, TTT into TCT) into pRK5-IRAK-1 expres-
sion vector, resulting in a F196S amino acid polymorphism that
has been reported in the NCBI protein database (accession nos.T
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P51617, F196 and AAC41949, S196). We designated the vector
encoding F196, phenylalanine, as “pRK5-IRAK-1 (N)” and the
vector encoding S196, serine, as “pRK5-IRAK-1 (M).”
The two IRAK-4 mutations found in the patient were intro-
duced into the WT pRK7-IRAK4 expression vector (N) by site-
directed mutagenesis and verified by sequencing. The primers 5
 
 
 
-
TGCAAGATTGCTTAGGGTGCAGCTAATG-3
 
 
 
 (forward)
and 5
 
 
 
-CATTAGCTGCACCCTAAGCAATCTTGCA-3
 
 
 
 (re-
verse) were used to introduce the C to T substitution at nucle-
otide 877 (877–879: CAG, normal; TAG, patient) into the WT
vector [pRK7-IRAK4 (N)], which creates a stop codon at amino
acid 293 [pRK7-IRAK4 (M #1)]. The primers 5
 
 
 
-ACG-
TAAATAACAACTGTGGCAGTGAAGAAG-3
 
 
 
 (forward) and
5
 
 
 
-CTTCTTCACTGCCACAGTTGTTATTTACGT-3
 
 
 
 (re-
verse) were used to introduce the AC deletion into pRK7-
IRAK4 at nucleotides 620–621 [pRK7-IRAK4 (M #2)].
 
Reporter Assays. 
 
As described previously (16), HEK293T
cells (provided by Dr. N. Rice, NIH, Bethesda, MD) were
seeded into 12-well plates (Costar) at 2 
 
 
 
 10
 
5
 
 cells/well. After
overnight incubation, cells were cotransfected for 3 h with
pCDNA3/huCD14, pCDNA3/huTLR4, pEFBOS/Flag-huMD-2
plasmids (0.1 
 
 
 
g/well each), the NF-
 
 
 
B reporter (0.5 
 
 
 
g/well)
and pCMV1-
 
 
 
Gal reporter (0.5 
 
 
 
g/well), and varying amounts
of pRK7-IRAK-4 (N) or pRK7IRAK4 (M #1) expression vec-
tors using SuperFect transfection reagent. To study the response
to IL-1
 
 
 
, the pCDNA3/huCD14, pCDNA3/huTLR4, and
pEFBOS/Flag-huMD-2 plasmids were omitted. After transfec-
tion, cells were incubated for 20 h, washed, and restimulated with
medium, LPS, or rIL-1
 
 
 
 for the indicated times. Cells were lysed
and luciferase activity was measured (16). Similar experiments
were performed to determine the effect of pRK7-IRAK-4 (N),
pRK7IRAK4 (M #1), and pRK7IRAK4 (M #2) expression on
IL-1
 
 
 
–stimulated IRAK-1 kinase activity as described above in
the 
 
In Vitro Functional Assays
 
 section for neutrophils.
 
Online Supplemental Material. 
 
To compare the capacity of
pRK5-IRAK-1 (N) and pRK5-IRAK-1 (M) vectors to reconsti-
tute IRAK-1 signaling, transient transfection of the IRAK-1–defi-
cient I1A clone of HEK293 cells (provided by Dr. X. Li, Cleve-
land Clinic Foundation, Cleveland, OH; references 17, 18) was
performed as described above in the 
 
Reporter Assays 
 
section
 
 
 
for
HEK293T cells that express IRAK-1 (16).
 
Results
 
Patient Response to Skin Blister Induction Is Abnormal.
This patient was originally found to be hyporesponsive to
i.v. challenge with LPS as evidenced by a subnormal febrile
response, failure to mobilize a normal leukocytosis, and sub-
normal elevations in plasma levels TNF- , IL-6, IL-8,
lactoferrin, and G-CSF (1). Fig. 1 shows that the patient also
had an abnormal inflammatory response to blister forma-
tion. Despite a normal early accumulation of exudate cells
into the blisters, the later phase ( 8 h) of neutrophil migra-
tion was markedly depressed ( 1.5 logs). The patient’s blis-
ter fluid had normal levels of C5a, but failed to accumulate
normal levels of IL-8, IL-6 (Fig. 1), and IL-1  (unpublished
data). Thus, the patient’s impaired inflammatory response
can be observed in the absence of a bacterial stimulus.
In Vitro Hyporesponsiveness to rIL-18.  The patient’s leu-
kocytes were shown previously to be LPS- and IL-1 hy-
poresponsive, whereas responses to other inflammatory
stimuli were normal. In the same year as the identification
of TLR4 as the LPS signal transducer, Thomassen et al.
(19) found that, like IL-1, the IL-18 signaling pathway used
IRAK-1 and TRAF6. Fig. 2 shows that normal T cells re-
spond to rIL-18 with a dose-dependent induction of IFN- .
In contrast, the patient’s cells failed to respond to rIL-18,
although the response to PMA plus ionomycin was normal.
In 1998, positional cloning of murine tlr4 led to the
identification of the elusive “Lps” gene (2, 3); however, the
point mutation in the intracytoplasmic domain of TLR4
Figure 1. Patient exhibits impaired inflammatory response to blister
formation in vivo. The panels show the accumulation of inflammatory
cells and mediators in the medium bathing the exposed dermal surface
versus time. In each panel, the value at t   0 represents the background
levels found in the 70% autologous serum. The shaded area represents the
95% confidence limits of the arithmetic mean (C5a; linear scale data) and
geometric means (exudative cells, IL-8, and IL-6; log scale data) of the re-
sponses of normal subjects (n   7). Patient data (solid line) represents the
mean of two experiments.
Figure 2. Patient exhibits impaired IL-18 responsiveness in vitro. T
cells from normal (NL; open symbols) controls or the patient (PT; closed
circles) were stimulated with rIL-18 and levels of IFN-  measured in cul-
ture supernatants. PMA and ionomycin (ION) treatment was used as a
positive control for nonreceptor-mediated stimulation of IFN- .T
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that renders C3H/HeJ mice LPS hyporesponsive did not
affect sensitivity of C3H/HeJ macrophages to rIL-1  (20).
Because our patient failed to respond to LPS and IL-1, as
well as IL-18, we hypothesized that her hyporesponsiveness
was not related to TLR4 per se, but rather, to a signaling
component shared by the three receptor systems.
Downstream Effectors of TLR4 or IL-1 Signaling Are Poorly
Activated in Patient’s PBMCs and Result in Diminished LPS-
induced Gene Expression.  Nuclear translocation of NF- B
and AP-1, as well as activation of mitogen-activated pro-
tein kinases, are consequences of both TLR and IL-1R sig-
naling. Fig. 3 A compares the response of a control (nor-
mal) versus the patient’s PBMCs to stimulation with LPS
or rTNF-  for activation of NF- B by EMSA. Control
PBMCs responded robustly to LPS and TNF- , whereas
the patient responded to TNF-  only. Fig. 3 B shows that
AP-1 translocation was strongly up-regulated by LPS in
normal PBMCs, whereas the patient’s PBMCs responded
only slightly above the medium-treated background.
Fig. 4 illustrates that PBMCs from the patient show re-
duced phosphorylation of p38 mitogen-activated protein
kinase in response to LPS or IL-1 . Although not com-
pletely eliminated, the patient’s response was consistently
lower when compared with an unrelated control (Fig. 4 A)
or to her sister (Fig. 4 B). Fig. 4 B also confirms that the
patient’s responsiveness to rTNF-  to induce p38 phos-
phorylation was normal.
TLR4- and IL-1–induced gene expression is mediated by
the action of transacting factors such as NF- B and AP-1,
and of kinases such as p38 (for review see reference 5).
Kuhns et al. (1) showed that this patient’s PBMCs failed to
secrete a number of proinflammatory cytokines when stimu-
lated by LPS. Fig. 5 extends these findings at the level of
gene expression and illustrates that her immediate family ex-
hibits normal LPS responsiveness. Fig. 5 A shows that both
parents were comparably LPS responsive, as indicated by
the capacity of their PMBCs to respond to LPS to increase
steady-state levels of TNF-  and Cox-2 mRNA, whereas
steady-state mRNA levels for TLR4 and for the house-
keeping gene, hypoxanthine-guanine phosphoribosyltrans-
ferase (HPRT), were not modulated, as we reported previ-
ously in elutriated monocytes (14). Fig. 5 B shows that
PBMCs from the father, sister, and an unrelated donor all
responded strongly and comparably to LPS to increase
TNF- , GM-CSF, and Cox-2 gene expression, indicating
normal LPS responsiveness. In contrast, the patient’s PBMCs
responded poorly to LPS with minimal up-regulation of
these genes. Steady-state mRNA levels for a number of
signaling intermediates common to the TLR4 and IL-1R
pathways (e.g., MyD88, Tollip, IRAK-1, and TRAF-6)
were also measured. The patient’s PBMCs expressed normal
basal levels of these mRNA species, which were not modu-
lated by LPS in either patient or control cells. Housekeep-
ing genes (e.g.,  -actin and HPRT) were expressed compa-
rably in all samples. Collectively, these data strongly indicate
that the parents and sibling of this LPS-hyporesponsive pa-
tient exhibit normal LPS responsiveness.
LPS-induced IRAK-1 Kinase Activity Is Dysregulated in the
Patient’s Neutrophils.  After MyD88 recruitment to TLR4
or the IL-1R, there is a transient phosphorylation of
Figure 3. Patient’s PBMCs exhibit impaired NF- B (A) and AP-1 (B)
translocation in response to LPS. PBMCs derived from a control or the
patient were stimulated with 1  g/ml LPS or 100 ng/ml rTNF-  for 60
min, and NF- B and AP-1 translocation assessed by EMSA.
Figure 4. Patient’s PBMCs exhibit impaired p38
phosphorylation in response to LPS or IL-1. PBMCs
derived from an unrelated control or the patient (A) or
the patient’s sister and the patient (B) were stimulated
with 1  g/ml LPS, 100 ng/ml rIL-1 , or 100 ng/ml
rTNF-  for 15 min. Whole cell lysates were analyzed
by Western blot analysis for phosphorylated p38 or to-
tal ERK-1,2.T
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IRAK-1 before it associates with TRAF6 and is ultimately
targeted to the proteosome (21). Fig. 6 illustrates that the
response of the patient’s neutrophils to LPS, as measured by
the capacity of immunoprecipitated IRAK-1 to phosphor-
ylate the exogenous substrate, MBP, is dysregulated. In
normal neutrophils, LPS induces a rapid and transient in-
duction of IRAK-1 kinase activity that typically peaks 3–4
min after stimulation. This pattern of normal LPS-induc-
ible IRAK-1–associated kinase activity was observed in
 10 donors (unpublished data). In contrast, the patient’s
response to LPS was abnormal. In this experiment, the pa-
tient’s baseline level of IRAK-1 kinase activity was initially
higher than in the control, but kinase activity was rapidly
lost upon LPS stimulation. By 5 min after stimulation, just
as the control’s kinase activity is decreasing to baseline lev-
els, the patient’s response is increasing to her baseline.
Western blot analysis for total levels of ERK-1,2 in the cel-
lular lysates used for anti–IRAK-1 immunoprecipitation
show that total protein did not differ significantly from
sample to sample in the normal versus patient cell lysates.
Although an anti–IRAK-1 Ab was used to immunoprecip-
itate lysates for the kinase assay, recent papers have shown
that IRAK-4 is necessary for activation of IRAK-1 kinase
activity (8, 9) and that MyD88, IRAK-4, and IRAK-1
form a complex (7). Therefore, the observed phosphoryla-
tion of MBP may be attributable to the combined kinase
activities of IRAK-1 and/or IRAK-4.
Cloning and Sequencing of Genes Common to TLR4 and IL-1
Signaling Pathways.  When these studies were initiated,
little was known about the signaling intermediates required
for TLR4 and IL-1R–mediated signaling. Nonetheless, we
cloned and sequenced candidate genes from controls and
the patient as GenBank/EMBL/DDBJ sequences became
available. Specifically, the transmembrane and intracyto-
plasmic CDS for both TLR4 and TLR2 were cloned from
cDNA (i.e., we hypothesized that a mutation in one of
these regions could sequester shared signaling molecules,
thus precluding their interaction in response to LPS or IL-
1 ) and found the patient to be normal. We sequenced
MyD88 from genomic DNA and cDNA and found no
mutations, and when anti-MyD88 Ab became available,
we confirmed that the patient’s MyD88 migrated normally.
We also cloned and sequenced Tollip, IRAK-2, IRAK-M,
ECSIT, and TRAF6, and no polymorphisms were identi-
fied (unpublished data). However, when we sequenced
IRAK-1 and IRAK-4 cDNA, we identified three muta-
tions that will now be discussed in detail.
Previous papers in mice with a targeted mutation in
IRAK-1 demonstrated that this protein is important in
TLR4-, IL-1–, and IL-18–mediated signaling (22, 23). The
IRAK-1 polymorphism identified in our patient was a sin-
gle nucleotide substitution of T to a C at cDNA nucleotide
666 [Control: nucleotides 665–667   TTT, amino acid  
phenylalanine (F); Patient: nucleotides 665–667   TCT,
amino acid   serine (S)]. Based on sequence analysis of
multiple clones, the patient was heterozygous for this poly-
morphism. Although this polymorphism had been reported
in GenBank/EMBL/DDBJ (accession no. AAC41949), we
did not know if its expression interfered with LPS- or IL-
1–induced signaling. Transient transfection of the IRAK-
1–deficient HEK293 cell line, IA1 (17), with either a
“WT” IRAK-1 expression vector (pRK5-IRAK-1 [N]) or
a vector generated by site-directed mutagenesis that en-
codes the alternate form expressed by the patient (pRK5-
IRAK-1 [M]), or equal amounts of both vectors, led to full
and comparable restoration of IL-1–induced NF- B re-
porter gene expression (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20030701/DC1). There-
fore, this IRAK-1 (T666C) polymorphism was not func-
tionally meaningful.
When we cloned and sequenced the patient’s IRAK-4
cDNA, two distinct mutations were identified. The first
was a C to T substitution at cDNA nucleotide 877 (which
corresponds to genomic DNA nucleotide 21175). This
substitution creates an in-frame, stop codon (Fig. 7 A; nu-
cleotides 877–879 are changed from CAG in the WT to
TAG in the patient’s gene). Five independent cloning ex-
periments (including normal donors in each case) were per-
formed in which random selection and sequencing of the
patient’s individual clones showed heterozygous expression
Figure 5. Patient’s PBMCs exhibit impaired LPS-induced gene ex-
pression; LPS-sensitivity of patient’s family members is normal. PBMCs
were stimulated with 100 ng/ml LPS for 3 h, and RNA was extracted for
analysis of gene expression by RT-PCR with Southern blot analysis. (A)
Comparison of responses of the patient’s mother and father; (B) Compar-
ison of father, sister, unrelated control, and patient responses.
Figure 6. Patient’s neutrophils
exhibit dysregulated IRAK-1 ki-
nase activity. Control and patient
neutrophils were stimulated with
100 ng/ml LPS for the indicated
times. Cell lysates were immu-
noprecipitated with anti–IRAK-1
Ab, and immunoprecipitates were
assayed for the capacity to phos-
phorylate MBP. Western blot
analysis for total ERK-1,2 was
performed on lysates before im-
munoprecipitation to ensure equal
protein concentrations (n   2).T
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of WT and mutated forms. In each experiment, an equiva-
lent number of clones from normal individuals were se-
lected and sequenced and in no case did we see expression
of the mutated form in any of these clones. The presence of
this mutation was confirmed by direct sequencing of PCR
products derived from the patient’s genomic DNA (i.e.,
there was a C/T overlap at nucleotide 21175). Also, direct
cloning of these PCR products, followed by sequencing,
revealed that approximately half the clones expressed C and
the other half expressed T, confirming heterozygosity of
this mutation (unpublished data).
Functional Analysis of IRAK-4 Point Mutation.  The
stop codon created by C877T is predicted to encode a
truncated form of IRAK-4, resulting in a protein of 292
amino acids versus the WT form that is 460 amino acids,
with estimated molecular weights of  30 kD and  50
kD, respectively. Attempts to detect endogenous full-
length or truncated forms of IRAK-4 by Western blot
analysis with an anti–IRAK-4 Ab (Tularik, Inc.) in the
same immunoprecipitates used for the neutrophil IRAK-1
kinase assays were unsuccessful, probably due to low en-
dogenous protein levels. Therefore, we used site-directed
mutagenesis to introduce the C to T point mutation into
the pFlagRK7-IRAK4 (N) WT expression vector. After
verifying the sequences of these vectors, we expressed the
normal or mutated (pFlagRK7-IRAK4 [M #1]) vectors in
IRAK-1–competent HEK293T cells. Fig. 7 B shows that
this single nucleotide substitution resulted in expression of
a protein that was significantly smaller than WT IRAK-4,
but slightly larger than predicted from the amino acid
sequence only, suggesting additional posttranscriptional
modification. Based on analysis of the IRAK-4 sequence
using the Expasy Translate Tool and EMBL-EBI EM-
BOSS-Transseq programs (http://us.expasy.org/cgi-bin/
dna_sequences and http://www.ebi.ac.uk/servicestmp,
respectively), the DD encompasses amino acids 20–104,
whereas the kinase domain spans amino acids 186–456.
Therefore, this point mutation truncates the IRAK-4 mol-
ecule within the kinase domain.
S. Li et al. (8) reported that overexpression of
pFlagRK7-IRAK4 (N) increased NF- B reporter activity
 10-fold in a subclone of HEK293 cells. They also
showed that the response of another HEK293 clone to IL-1
could be inhibited in a dose-dependent manner by overex-
pression of a kinase-defective mutant (KK213AA) or a
truncated form consisting of the NH2-terminal 191 amino
acids. Although we were able to drive NF- B reporter ac-
tivity by IRAK-1 overexpression in our HEK293T cells,
neither WT (N) nor mutant IRAK-4 (M #1) vectors acti-
vated NF- B reporter activity (Fig. 7 C). Moreover, when
we cotransfected the HEK293T cells with constructs that
would enable LPS responsiveness (i.e., CD14, TLR4, and
MD-2), expression of the WT IRAK-4 down-regulated
LPS-induced NF- B reporter activity, whereas expression
of the mutated form (M #1) failed to inhibit (Fig. 8 A,
left). This was also the case for IL-1–stimulated NF- B re-
porter activity (Fig. 8 A, right). These findings were con-
firmed in another HEK293 cell line stably transfected with
TLR4 and MD-2 (unpublished data), and suggests that the
mutant lacks a domain that is critical for sequestration of
signaling molecules under conditions of overexpression in
our HEK293 cell lines.
Figure 7. Identification and functionality of a point mutation in patient’s
IRAK-4. (A) Illustration of C877T substitution mutation (M #1), resulting
in a truncated form of IRAK-4. Arrow indicates approximate location of
truncation in IRAK-4 protein. (B) Vectors encoding the WT (N) or
C877T mutation (M #1) forms of IRAK-4 were expressed in HEK293T
cells (5  g vector/transfection) and cell lysates subjected to Western blot
analysis using anti-Flag Ab. (C) Overexpression of WT (N) or C877T (M
#1) forms of IRAK-4 in HEK293T cells failed to induce NF- B–induced
reporter activity. Cells were transiently transfected with pELAM-Luc,
pCMV- Gal, and the indicated amounts of expression vectors encoding ei-
ther IRAK-1 or normal (N) and mutated (M) forms of IRAK-4 (total
amount of plasmid DNA was kept constant at 1.5  g per transfection). Af-
ter recovery for 48 h, NF- B reporter activity was measured. The data rep-
resent the mean   SEM of a representative experiment (n   3).T
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To test directly the capacity of the truncated IRAK-4 to
activate IRAK-1 kinase activity, HEK293T cells were
transfected with a control vector, pCDNA 3.1, the WT
IRAK-4 vector, or the mutant (M #1) IRAK-4 vector.
Transfectants were stimulated with rIL-1, and IRAK-1 was
immunoprecipitated from cell lysates and assayed for the
capacity to phosphorylate MBP. Fig. 8 B illustrates that, in
contrast to the WT IRAK-4 construct that enhanced IL-1–
induced IRAK-1 kinase activity in the HEK293T cells,
overexpression of the mutant not only failed to enhance
endogenous kinase activity, but also inhibited it.
Identification of a Second IRAK-4 Mutation.  Both the pa-
tient’s parents responded vigorously to LPS (Fig. 5 A) and
neither exhibited a history of recurrent infection. There-
fore, we hypothesized that a second mutation on the pa-
tient’s alternate IRAK-4 allele must be present to ac-
count for such a profound phenotype. A two-nucleotide
deletion was identified in the cDNA at nucleotides 620–
621, which corresponds to genomic DNA nucleotides
15978–15979. This second mutation was not seen in any
clones that carried the point mutation, supporting the hy-
pothesis that it was derived from the alternate allele. The
predicted effect of this frameshift mutation would be to
create a stop codon 36–39 nucleotides downstream in the
IRAK-4 CDS, resulting in a second truncated form with a
predicted size of 218 amino acids or  22 kD (Fig. 9 A) and
would be predicted to express the entire DD, but a smaller
region of the kinase domain than M #1. As in the case of
the point mutation, the presence of the mutation was con-
firmed by sequencing PCR products amplified from geno-
mic DNA that showed a C/A double peak at nucleotide
Figure 8. (A) Overexpression of WT (N), but not C877T mutant (M),
IRAK-4 expression vector inhibits LPS- and IL-1–mediated signaling in
HEK293T cells. Cells were transiently transfected as described in Fig. 7,
permitted to recover for 48 h, and stimulated with medium, LPS, or rIL-
1  for 5 h before measurement of NF- B reporter activity. (B) Overex-
pression of WT (N), but not C877T mutant (M), IRAK-4 expression
vectors differentially modulate IRAK-1 kinase activity. Cells were tran-
siently transfected with control pCDNA3.1, pRK7-IRAK4 (N), or
pRK7-IRAK4 (M; 5  g per transfection). After 40 h recovery, cells were
stimulated with rIL-1  for the indicated times, followed by lysis of cells
and the IRAK-1 kinase assay (n   3).
Figure 9. Identification and functionality of deletion mutation in pa-
tient’s IRAK-4. (A) Illustration of effect of AC deletion at nucleotides
620-621 in the patient (620-621del), resulting in a truncated form of
IRAK-4 (M #2). Arrow indicates approximate location of truncation in
IRAK-4 protein. (B) Vectors encoding the WT (N) or mutated (M #2)
forms of IRAK-4 were expressed in HEK293T cells (10  g vector/trans-
fection), and cell lysates subjected to Western blot analysis using anti-Flag
Ab as described in Fig. 8. (C) Overexpression of WT (N), but not the
620-621 deleted mutant (M #2), IRAK-4 expression vectors (10  g/
transfection) differentially modulate IRAK-1 kinase activity (see Fig. 8 B;
n   3).T
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623 with a scrambled sequence thereafter (unpublished
data). In addition, sequencing of cloned PCR products
confirmed that approximately half expressed the deletion.
Using site-directed mutagenesis, we introduced the dele-
tion into the pRK7-FlagIRAK4 (N) expression vector to
obtain the mutant vector, pRK7-IRAK4 (M #2) and
overexpressed both in HEK293T cells to compare them
functionally. Fig. 9 B shows that pRK7-IRAK4 (M #2)
led to expression of two truncated Flag-tagged proteins
with molecular weights of  26 and 30 kD, suggesting
posttranscriptional modification, and/or possibly “read
through” of the first stop codon. Fig. 9 C demonstrates
that, unlike WT IRAK-4, this more-truncated form of
IRAK-4 also failed to augment endogenous IRAK-1 ki-
nase activity and inhibited endogenous basal and IL-1–
induced IRAK-1 activity, although less than observed
upon overexpression of pRK7-IRAK4 (M #1).
Discussion
We described previously our patient as having a long
history of severe, recurrent bacterial infections and greatly
diminished responses to LPS in vivo or to LPS and IL-1 in
vitro (1), and speculated that this phenotype was due to a
defect early in the LPS signal transduction pathway. In ad-
dition to abnormal LPS and IL-1 signaling, we now show
that this patient’s T cells failed to respond to rIL-18 to se-
crete IFN-  (Fig. 2). Our findings that LPS- or IL-1–
induced NF- B and AP-1 translocation, p38 phosphoryla-
tion, or LPS-induced gene expression were all impaired in
this patient’s PBMCs (Figs. 3–5) provided strong evidence
for an upstream signaling defect shared by all three receptor
systems. This was further strengthened by the observation
that this patient exhibited dysregulated neutrophil IRAK-1
kinase activity in response to LPS. Rather than being in-
creased by LPS, IRAK-1 kinase activity was transiently
down-regulated, suggesting an inhibitory effect of this mu-
tation on IRAK-1 kinase activity. Although sequence anal-
ysis of this patient’s IRAK-1 gene revealed a heterozygotic
polymorphism (F196S) located in a critical region of the
protein (i.e., just upstream of the region that encodes the
kinase domain; reference 19), it fully reconstituted signal-
ing in IRAK-1–deficient cells (Fig. S1).
However, this patient also possesses a “compound het-
erozygous” genotype in IRAK-4. The expression of dis-
tinct mutations on each of the patient’s IRAK-4 alleles re-
sults in the failure to express a normal gene product (i.e., a
“compound heterozygous genotype” that results in a reces-
sive phenotype). Generally, inheritance of a compound
heterozygous genotype leading to a recessive phenotype is
more common than expression of homozygous recessive
mutations, particularly in diseases where many different
mutations have been reported (e.g.,  -globin; references
24, 25). The two distinct mutations in this patient encode
proteins that, when expressed, are truncated within the
IRAK-4 kinase domain, yet retain the entire DD. Al-
though overexpression of the WT IRAK-4 vector in
HEK293T cells augmented IRAK-1 kinase activity in-
duced by IL-1, overexpression of the mutant forms inhib-
ited endogenous IRAK-1 kinase activity modestly, indicat-
ing that these molecules do not function normally and can
interfere with WT IRAK-4 (i.e., exhibit dominant nega-
tive activity) when coexpressed with a normal IRAK-4
gene. These data are consistent with those of S. Li et al. (8)
in which a 193 amino acid form of IRAK-4, or one that
expresses mutations within the kinase domain, were found
to inhibit IL-1–mediated signaling in a subline of HEK293
cells. Sequencing analysis revealed that the patient’s father
was heterozygous for the point mutation (i.e.,  /C877T
genotype), whereas her mother and sister were heterozy-
gous for the deletion mutation (i.e.,  /620–621del geno-
type), yet both parents and her sibling are fully LPS respon-
sive, based on a history of normal febrile response to
bacterial infections, no history of repeated infections, and
normal LPS-inducible gene expression in vitro. One can
only assume that compared with overexpression systems in
vitro, the levels of expression of each of the mutated forms
by the parents is insufficient to block activity of the their
WT IRAK-4 such that LPS responsiveness is not measur-
ably impaired. Therefore, gene therapy may be a viable ap-
proach for this patient.
The central role of IRAK-4 in LPS- and IL-1 signaling
has only recently emerged. Work by S. Li et al. (8), pub-
lished within the past year, indicates that IRAK-4 activa-
tion is required for phosphorylation of IRAK-1. This is
consistent with earlier work of X. Li et al. (18), who
showed that the IRAK-1 kinase domain is unnecessary for
reconstitution of phosphorylation of IRAK-1 and signaling
in IRAK-1–deficient cells. These authors postulated the
existence of an upstream kinase that elicits the initial phos-
phorylation of IRAK-1 in response to IL-1. Although
other IRAK family members (e.g., IRAK-2 and IRAK-M)
can substitute for IRAK-1 (for review see reference 6), the
necessity of IRAK-4 is further supported by the strong
LPS- and IL-1–resistant phenotypes in mice with a targeted
mutation in IRAK-4 (9). Burns et al. (7) demonstrated an
interaction of MyD88, IRAK-4, and IRAK-1; IRAK-1
interacts with MyD88 through homotypic DD interac-
tions, whereas the region of MyD88 between the TIR and
DD is necessary for recruitment of IRAK-4, although the
region on IRAK-4 that engages MyD88 was not reported.
In coimmunoprecipitation experiments, we have found
that overexpression of either truncated form (M #1 or M
#2) in HEK293T cells results in a stronger association with
MyD88 than WT IRAK-4 (unpublished data). This sug-
gests that the DD of IRAK-4 enables it to bind to the re-
gion of MyD88 between its TIR and DD (7), and suggests
the possibility that dominant negative inhibition may be fa-
cilitated through preferential or sustained binding of trun-
cated forms. When coupled with the failure of the trun-
cated form to compete for signaling components leading to
inhibition of NF- B reporter activity (Fig. 8 A; WT
IRAK-4), their failure to augment IRAK-1 kinase activity,
and their capacity to inhibit endogenous IRAK-1 kinase
activity when overexpressed (Figs. 8 B and 9 C), a model
of interaction between MyD88 and truncated IRAK-4, butT
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not between truncated IRAK-4 and downstream signaling
molecules, is suggested.
Quite recently, three unrelated patients with homozy-
gous recessive IRAK-4 deficiencies were identified (26).
Like our patient, these patients had recurrent pyogenic in-
fections. Our patient expresses a unique pattern of IRAK-4
insufficiency as a consequence of her compound heterozy-
gosity, further supporting the essentiality of IRAK-4 in the
response to bacterial infection. Unquestionably, the most
fascinating aspect of these two independent papers is that
the substitution of T for C at nucleotide 877 of the IRAK-4
cDNA (C877T) is common to our patient and two of the
patients described in the other paper. Because these patients
are, to the best of our knowledge, unrelated, the data sug-
gest that this site may represent a hypermutable site or “hot
spot” in this gene. Coupled with the fact that our patient
expresses a compound heterozygous genotype, these data
suggest that there are likely to be additional patients that fail
to express functional IRAK-4 and present with recurrent
bacterial infections.
The data in this report also provide compelling new evi-
dence for an important role for IRAK-4 in mobilizing the
acute inflammatory response. The observation that our pa-
tient also fails to mount a normal inflammatory response in
response to blister formation suggests that the role for
IRAK-4 in inflammation is not restricted to pyogenic stim-
uli, as suggested by Picard et al. (26). Specifically, in re-
sponse to skin blister induction, our patient had normal
acute (3–5 h) cellular inflammation with normal levels of
C5a, but impaired delayed (8–24 h) cellular inflammation
with depressed levels of IL-8 and other proinflammatory
cytokines. Normal levels of C5a, and presumably of other
chemoattractants not measured (i.e., leukotriene B4), that
do not require the TLR pathway for synthesis, likely ac-
count for the normal, early phase of inflammation. Our pa-
tient’s diminished capacity to produce IL-8 and other
proinflammatory cytokines likely explains the defective
later phase of acute inflammation in the blister model. The
defective production of inflammatory mediators identified
in our patient as a result of mutations in IRAK-4 provides
strong evidence for the importance of IRAK-4 and prod-
ucts of the TLR pathway in mobilizing the inflammatory
response in vivo. It is also possible that the release of en-
dogenous, cell-derived TLR agonists released as a conse-
quence of the inflammatory response to blister formation
provides the necessary stimulus for this later inflammatory
response. In this regard, Kuhns et al. (27) and Smiley et al.
(28) reported that fibrinogen is a potent TLR4 agonist,
leading to the induction of chemokine expression; our pa-
tient also fails to respond to fibrinogen in vitro (unpub-
lished data). Finally, the absence of increased susceptibility
to viral and fungal infections in our patient further suggests
that IRAK-4–independent pathways must also be triggered
in host defense against these infections.
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